Global Alzheimer's Disease Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Cholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonist, and Others.

By Disease Indication;

Mild-To-Moderate Alzheimer's Disease and Moderate-To-Severe Alzheimer's Disease.

By Severity Type;

Mild, Moderate, and Severe.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn102533253 Published Date: April, 2025 Updated Date: May, 2025

Introduction

Global Alzheimer's Disease Therapeutics Market (USD Million), 2021 - 2031

In the year 2024, the Global Alzheimer's Disease Therapeutics Market was valued at USD 8,762.30 million. The size of this market is expected to increase to USD 13,140.49 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.


Global Alzheimer's Disease Therapeutics Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 6.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.0 %
Market Size (2024)USD 8,762.30 Million
Market Size (2031)USD 13,140.49 Million
Market ConcentrationMedium
Report Pages360
8,762.30
2024
13,140.49
2031

Major Players

  • Allergan Plc
  • Biogen, Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • Johnson & Johnson
  • AstraZeneca plc
  • AbbVie, Inc.
  • Eli Lilly & Company
  • Takeda Pharmaceutical Company Ltd.
  • TauRx Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • Otsuka Pharmaceutical Co., Ltd.
  • H. Lundbeck A/S
  • NeuroBio Pharmaceuticals
  • Avanir Pharmaceuticals, Inc.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Alzheimer's Disease Therapeutics Market

Fragmented - Highly competitive market without dominant players


Alzheimer's Disease, a progressive neurodegenerative disorder, presents one of the most pressing challenges in global healthcare today. With an aging population worldwide, the prevalence of Alzheimer's is steadily rising, compelling the healthcare industry to intensify efforts in developing effective therapeutics. The Global Alzheimer's Disease Therapeutics Market stands at the forefront of this battle, driven by relentless research and innovation to alleviate the burden of this debilitating condition.

Significant strides have been made in understanding the underlying mechanisms of Alzheimer's Disease, leading to the emergence of novel therapeutic approaches. From traditional pharmaceutical interventions aimed at mitigating symptoms to cutting-edge biotechnological advancements targeting disease-modifying pathways, the landscape of Alzheimer's therapeutics is undergoing rapid transformation. This evolution is not only reshaping treatment paradigms but also fostering hope for improved patient outcomes and enhanced quality of life.

However, despite notable progress, formidable challenges persist in the pursuit of effective Alzheimer's treatments. From regulatory hurdles to the complexity of the disease itself, stakeholders across the healthcare continuum face multifaceted obstacles. Nevertheless, with growing awareness, collaborative research efforts, and expanding investment, the Global Alzheimer's Disease Therapeutics Market continues to forge ahead, driven by a shared commitment to combatting this pervasive illness and offering solace to millions affected worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Disease Indication
    3. Market Snapshot, By Severity Type
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Alzheimer's Disease Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Aging Population
        2. Increasing Disease Prevalence
        3. Rising Healthcare Investment
      2. Restraints
        1. High Development Costs
        2. Limited Efficacy of Current Therapies
        3. Patent Expirations
      3. Opportunities
        1. Novel Drug Targets
        2. Personalized Medicine
        3. Patient Education
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Alzheimer's Disease Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)

      1. Cholinesterase Inhibitors
      2. N-Methyl-D-Aspartate Receptor Antagonist
      3. Others
    2. Alzheimer's Disease Therapeutics Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Mild-To-Moderate Alzheimer's Disease
      2. Moderate-To-Severe Alzheimer's Disease
    3. Alzheimer's Disease Therapeutics Market, By Severity Type, 2021 - 2031 (USD Million)
      1. Mild
      2. Moderate
      3. Severe
    4. Alzheimer's Disease Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Alzheimer's Disease Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Allergan Plc
      2. Biogen, Inc.
      3. Novartis AG
      4. Merck & Co., Inc.
      5. Eisai Co., Ltd.
      6. Johnson & Johnson
      7. AstraZeneca plc
      8. AbbVie, Inc.
      9. Eli Lilly & Company
      10. Takeda Pharmaceutical Company Ltd.
      11. TauRx Therapeutics Ltd.
      12. Bristol-Myers Squibb Company
      13. Otsuka Pharmaceutical Co., Ltd.
      14. H. Lundbeck A/S
      15. NeuroBio Pharmaceuticals
      16. Avanir Pharmaceuticals, Inc.
  7. Analyst Views
  8. Future Outlook of the Market